Population Pharmacokinetics of Ibuprofen Enantiomers in Very Premature Neonates

Journal of Clinical Pharmacology - Tập 44 Số 10 - Trang 1114-1124 - 2004
Nicolas Grégoire1, Virginie Gualano1, Anne Geneteau1, L Millérioux1, Murielle Brault1, A Mignot1, Jean‐Christophe Rozé2
1Aster-Cephac, Saint-Benoit, France
2Department of Neonatology, University Hospital of Nantes, France

Tóm tắt

The objective of the present study was to evaluate the pharmacokinetic parameters for both S‐ and R‐ibuprofen enantiomers in very premature neonates (gestational age strictly inferior to 28 weeks) and possible relationships between the pharmacokinetic parameters and various covariates. Newborns were randomized to receive ibuprofen or placebo for the prophylactic treatment of patent ductus arteriosus (PDA) at an initial dose of 10 mg/kg ibuprofen within 6 hours after birth, followed by two 5‐mg/kg doses at 24‐hour intervals (n = 52). If a PDA was still present afterwards, a curative course of ibuprofen using the same dosage regimen was administered (n = 10). A sparse sampling strategy was used because only 2 samples were collected after the third prophylactic injection and 1 after the third curative injection. A model including the chiral transformation of R‐ to S‐ibuprofen was fitted to the concentration‐time data using a population approach (NONMEM). R‐ and S‐ibuprofen t1/2 were about 10 hours and 25.5 hours, respectively. After prophylactic treatment, the mean clearance of R‐ibuprofen (CLR = 12.7 mL/h) was about 2.5‐fold higher than for S‐ibuprofen (CLS = 5.0 mL/h). In addition, clearance of R‐ and S‐ibuprofen increased significantly with gestational age. The mean estimation of R‐ibuprofen clearance was found to be higher than for S‐ibuprofen, and the clearance of both enantiomers increased with gestational age. This should be considered to assess pharmacokinetic‐pharmacodynamic relationships of ibuprofen in premature neonates and subsequently to understand and refine the use of ibuprofen in managing PDA either as a prophylactic or curative treatment.

Từ khóa


Tài liệu tham khảo

10.1007/BF02265403

10.1016/S0022-3476(85)80361-9

10.1016/S0022-3476(83)80022-5

10.1067/mpd.2000.103414

10.1136/fn.74.2.F81

10.1016/S0022-3476(88)80225-7

10.1203/00006450-199107000-00021

10.1159/000014165

10.1136/fn.76.3.F179

Van OvermeireB LanghendriesJP VanhaesebrouckP et al.Ibuprofen for early treatment of patent ductus arteriosus a randomised multicenter trial [poster 1167]. Poster presented at the meeting of the American Pediatric Society New Orleans La May 1998 and NEJM September 2000.

10.1007/s00431-002-0915-y

Varvarigou N, 1996, Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants, JAMA, 275, 539, 10.1001/jama.1996.03530310045031

Aranda JV, 1994, Place de l'inhibition de la cyclo‐oxygenase par l'ibuprofène dans la prévention des lésions cérébrales du nouveau‐né, Progrès en Néonatalogie, 14, 12

Bray M, Efficacy and safety of prophylaxis with ibuprofen in 111 preterm infants with RDS, Pediatrics

10.1007/s004310051288

10.1111/j.2042-7158.1976.tb04144.x

10.1023/A:1018969506143

10.2165/00003495-198938020-00006

10.1111/j.1651-2227.1997.tb08892.x

10.1016/S0009-9236(01)13478-8

10.1016/S0140-6736(02)08424-6

10.1016/S0169-2607(98)00098-4

10.1002/j.1552-4604.1997.tb04326.x

10.2165/00003088-199834020-00002

10.1038/clpt.1992.128

10.1111/j.1365-2125.1994.tb04369.x

Thông tin
Thông tin xuất bản

Journal of Clinical Pharmacology

Tập 44 Số 10

1114-1124

Thông tin tác giả